Evidence map›Paper›PMID 33494379›Full record

ReviewAntioxidants (Basel, Switzerland)2021

Suicidal Erythrocyte Death in Metabolic Syndrome.

Ignazio Restivo, Alessandro Attanzio, Luisa Tesoriere, Mario Allegra

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Pathophysiology of Red Blood Cell Dysfunction in Diabetes and Its Complications.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023
    Review
  11. Molecular Mechanisms and Pathophysiological Significance of Eryptosis.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Review
  14. Cigarette Smoke Extract Induces p38 MAPK-Initiated, Fas-Mediated Eryptosis.International journal of molecular sciences · 2022
    Article
  15. Article
  16. Review
  17. Role of Eryptosis in Hemorrhagic Stroke.Frontiers in molecular neuroscience · 2022
    Review
  18. Review
  19. Usnic Acid andAntioxidants (Basel, Switzerland) · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ignazio RestivoDipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche Università di Palermo, 90128 Palermo, Italy.ORCID 0000-0003-1833-2356
Alessandro AttanzioDipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche Università di Palermo, 90128 Palermo, Italy.ORCID 0000-0002-6622-028X
Luisa TesoriereDipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche Università di Palermo, 90128 Palermo, Italy.ORCID 0000-0002-7980-7530
Mario AllegraDipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche Università di Palermo, 90128 Palermo, Italy.ORCID 0000-0002-5846-1868
University of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eryptosis is a coordinated, programmed cell death culminating with the disposal of cells without disruption of the cell membrane and the release of endocellular oxidative and pro-inflammatory milieu. While providing a convenient form of death for erythrocytes, dysregulated eryptosis may result in a series of detrimental and harmful pathological consequences highly related to the endothelial dysfunction (ED). Metabolic syndrome (MetS) is described as a cluster of cardiometabolic factors (hyperglycemia, dyslipidemia, hypertension and obesity) that increases the risk of cardiovascular complications such as those related to diabetes and atherosclerosis. In the light of the crucial role exerted by the eryptotic process in the ED, the focus of the present review is to report and discuss the involvement of eryptosis within MetS, where vascular complications are utterly relevant. Current knowledge on the mechanisms leading to eryptosis in MetS-related conditions (hyperglycemia, dyslipidemia, hypertension and obesity) will be analyzed. Moreover, clinical evidence supporting or proposing a role for eryptosis in the ED, associated to MetS cardiovascular complications, will be discussed.

Indexed as

atherosclerosisdiabetesdyslipidemiaendothelial dysfunctioneryptosishypertensionmetabolic syndromeobesityoxidative stressvascular damage

Identifiers

PMID33494379
PMCPMC7911029
OpenAlexW3125709859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.